Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

Purpura, Thrombocytopenic Clinical Trial

— RE-PTT  

Official title:

Development Of Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry (REPTT): A Study Proposal Of The Spanish Society Of Hematology And Hemotherapy (SEHH) Whit The Portuguese Society Of Hematology (SPH)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05914441
• Other study ID #: RE-PTT
• Status: Recruiting
• Start date: March 22, 2024
• Est. completion date: December 2026

Study information

• Verified date: May 2024
• Source: Fundación Española de Hematología y Hemoterapía
• Contact: Contact person Designated by the Sponsor
• Phone: +34934344412
• Email: investigacion[@]mfar.net
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

REPTT is an observational, prospective, multi-country, multicentre and non-interventional registry in which at least 300 patients with Thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal will be evaluated.

The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.

Description:

TTP is a rare life-threatening haematological disease characterised by thrombotic microangiopathy (TMA) with an average annual prevalence of approximately 10 cases/million people worldwide and an annual incidence between 1.5 and 6.0 cases per million according to different studies conducted in France, the United States and in the United Kingdom. In Spain the incidence is 2,67 cases / million population per year.

Acute TTP episodes cause sequelae like vascular disease or kidney damage along with other symptoms more subtle like small neurocognitive deficits and myocardial infarction.

Thus, prompt resolution of acute episodes along with a better understanding of the cardiac abnormalities may allow to prevent further complications, to develop targeted rehabilitation techniques for TTP patients and to improve their quality of life.

This project will collect a big database capable of providing better answers to questions related with treatment efficacy, associated morbidity and mortality, and the possible neurocognitive and cardiac sequelae derived from relapses and acute episodes. Additionally, this project will be linked to obtaining biological samples for a serum and DNA library from patients with TTP.

Patients will be recruited by medical researchers specialized in haematology or by other investigators specialized in thrombotic microangiopathies disease management. This recruitment will be performed in a competitive manner. The collection period will be at least 3 years with the possibility of extending it.

REPTT aims to evaluate new scores and prognostic factors of morbidity and mortality in TTP patients.

The final aim is to establish guidelines and recommendation to improve the global management, diagnosis and treatment of patients with TTP in real-life.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 2026
• Est. primary completion date: September 2026
• Gender: All
• Age group: N/A to 99 Years

Eligibility

Inclusion Criteria:

1. Patients with diagnosis of TTP according to International Consensus criteria from centres in Spain and Portugal.

2. Patients that voluntarily sign the informed consent. For subjects unable to provide informed consent, a fully recognized medical authority may be used according to local laws.

3. Patients between 0 to 99 years old at the time of diagnosis.

Note: Decision was taken to treat the patient with an specific treatment prior and independently of patient inclusion in this non interventional study.

Exclusion Criteria:

1. Inability to comply with study procedures and follow-up exams.

2. Patients with any type of alteration that compromises their ability to grant written informed consent.

3. Patients that do not consent to participate in the study and do not sign informed consent.

4. Patients that do not meet the criteria previously mentioned for TTP.

Related Conditions & MeSH terms

• Purpura
• Purpura, Thrombocytopenic
• Purpura, Thrombotic Thrombocytopenic

Intervention

Other:
• Standard clinical practice
The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.

Locations

Country	Name	City	State
Spain	Hospital Clínic Barcelona	Barcelona
Spain	Hospital Universitario de Guadalajara	Guadalajara
Spain	Hospital Universitario Bellvitge	L'Hospitalet De Llobregat	Barcelona
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Virgen de la Arrixaca	Murcia
Spain	Hospital Universitario Virgen del Rocío	Sevilla	Andalucia
Spain	Hospital Clínico Universitario de Valencia	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Fundación Española de Hematología y Hemoterapía

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of TTP in Spain/Portugal	Number of patients diagnosed with TTP and enrolled in the registry per year	Throughout the study period, calculated for the 3 years of expected duration.
Primary	Morbidity of TTP in Spain/Portugal	Percentage of patients diagnosed with TTP and enrolled in the registry among spanish / portuguese population per year	Throughout the study period, calculated for the 3 years of expected duration.
Primary	Mortality of TTP in Spain/Portugal	Percentage of patients diagnosed with TTP and enrolled in the registry per year who died due to the disease	Throughout the study period, calculated for the 3 years of expected duration.
Secondary	Clinical response to treatment rate	Defined as sustained normalization of platelet counts above the lower limit of the established reference range and of lactate dehydrogenase (LDH) after cessation of plasma exchange. The number of patients that achieved clinical response and their frequency will be reported.	Throughout the study period, approximately 3 years per patient
Secondary	TTP Clinical remission rate	Defined as a clinical response after cessation of plasma exchange, maintained for > 30 days. The number of patients that achieved clinical remission and their frequency will be reported	Throughout the study period, approximately 3 years per patient
Secondary	TTP Exacerbation rate	Defined as a reduction in platelet count to below the lower limit of the established reference range, an increased LDH level, and the need to restart plasma exchange within 30 days of the last plasma exchange after a clinical response to plasma exchange. The number of patients with exacerbations and their frequency will be reported	Throughout the study period, approximately 3 years per patient
Secondary	TTP Relapse rate	Defined as a fall in platelet count to below the lower limit of the established reference range, with or without clinical symptoms, > 30 days after stopping of plasma exchange for an acute TTP episode, requiring reinitiation of therapy. This is usually associated with a new increase in the LDH level. The number of patients with relapse and their frequency will be reported.	Throughout the study period, approximately 3 years per patient
Secondary	Refractory TTP rate	defined as persistent thrombocytopenia, lack of a sustained platelet count increment or low platelet counts and a persistently raised LDH level despite five plasma exchanges 44 and steroid treatment. The number of patients with refractory TTP and their frequency will be reported.	Throughout the study period, approximately 3 years per patient
Secondary	Time-to-response (TTR)	Defined as the time from the date of first administration of treatment until the date of clinical response. Patients who die, are lost to follow-up, or reach the time point of analysis without a known record of response will have the TTR censored at the date of death, last assessment or last contact of a follow-up, whichever occurs last. Patients who received a new treatment for TTP whatever the type of treatment before disease response will be censored at the start date of this new treatment. The cumulative incidence of TTR will be estimated by the method of Kaplan-Meier.	Throughout the study period, approximately 3 years per patient
Secondary	Duration of response (DoR)	DoR will be calculated among those patients that achieve a clinical response from the time that measurement criteria are first met until the date of exacerbation, relapse, appearance of refractory TTP or death by any cause. Patients who are lost to follow-up, or reach the time point of analysis without a known record of TTP recurrence or death will have the DoR censored at the date of last assessment or last contact of a follow-up, whichever occurs last. Patients who received a new treatment for TTP, whatever the type of treatment, will be censored at the start date of this new treatment.	Throughout the study period, approximately 3 years per patient
Secondary	Relapse-free survival (RFS)	RFS will be calculated from the date of first administration of treatment until the date of TTP relapse or the date of death due to any cause. Patients who are lost to follow-up, or reach the time point of analysis without a known record of relapse or death will have the RFS censored at the date of last assessment or last contact, whichever occurs last. Patients who received a new treatment for TTP, whatever the type of treatment, before disease relapse or death will be censored at the start date of this new treatment. The cumulative incidence of relapse will be estimated by the method of Kaplan-Meier	Throughout the study period, approximately 3 years per patient
Secondary	Overall survival (OS)	OS will be calculated from the date of the first episode recorded until the date of death due to any cause. Patients who are lost to follow-up or reach the time point of analysis without a known record of death will have the OS censored at the date of last contact. The cumulative incidence of OS will be estimated by the method of Kaplan-Meier.	Throughout the study period, approximately 3 years per patient
Secondary	Frequency of serious adverse events (SAEs)	Percentage of patients who experience SAEs during the study	Throughout the study period, approximately 3 years per patient
Secondary	Rate of complications associated with plasma exchange treatment	Percentage of patients who experience complications associated with plasma exchange	Throughout the study period, approximately 3 years per patient
Secondary	Frequency of complications associated with plasma exchange treatment	Number of complications associated with plasma exchange per TTP event	Throughout the study period, approximately 3 years per patient